ProPhase Labs, Inc.
PRPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRPH
ProPhase Labs, Inc. is a next-generation biotech, genomics and consumer products company focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds and diagnostics, currently pursuing a reverse merger with Advanced Biological Laboratories S.A.
Key risk: Severe cash shortage
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for ProPhase Labs, Inc..
ProPhase Labs, Inc. is a next-generation biotech, genomics and consumer products company focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds and diagnostics, currently pursuing a reverse merger with Advanced Biological Laboratories S.A.
- ProPhase Labs is a next-generation biotech, genomics and consumer products company [sec_mda · as of 2026-06-30].
- As of June 30, 2026, the company had cash and equivalents of approximately $20,000 and a working capital deficit of $55.3 million [sec_mda · as of 2026-08-19].
- The company has entered into a non-binding Letter of Intent regarding a proposed reverse merger with Advanced Biological Laboratories S.A. (ABL) [sec · filed 2025-12-19].
- Its pipeline includes a preclinical PIM kinase inhibitor (lb-1) for cancer, inflammatory diseases, and memory-related syndromes, licensed from Global BioLife with milestone payments and royalties [pipeline].
- The company's COVID-19 diagnostic testing subsidiaries ceased providing testing in May 2025 [sec_mda · as of 2026-06-30].
What works
- The company has a preclinical PIM kinase inhibitor (lb-1) targeting multiple large indications (cancer, inflammatory diseases, dementia) with a licensed global partner [pipeline].
- Management estimates it has enough cash to finance operating requirements for at least 12 months from the filing date of the June 2026 quarterly report [sec_mda · as of 2026-08-19].
- The proposed reverse merger with ABL could provide a new strategic direction and access to European biotechnology assets [sec · filed 2025-12-19].
What to weigh
- As of June 30, 2026, cash and equivalents were only $20,000 with a working capital deficit of $55.3 million, indicating severe liquidity constraints [sec_mda · as of 2026-08-19].
- The company's COVID-19 diagnostic testing business ceased in May 2025, removing a major revenue source [sec_mda · as of 2026-06-30].
- The company has a going concern qualification in its financial statements, with no assurance that additional funding will be available on acceptable terms [sec_mda · as of 2026-08-19].
- The reverse merger with ABL is only at a non-binding LOI stage and may not be completed [sec · filed 2025-12-19].
From the filings
Quoted directly from source documents.
ProPhase Labs is a next-generation biotech, genomics and consumer products company.
“We are a next-generation biotech, genomics and consumer products company.”
SEC MD&A · June 30, 2026
Cash and equivalents were approximately $20,000 as of June 30, 2026.
“Our aggregate cash and cash equivalents as of June 30, 2026 were approximately $20,000”
SEC MD&A · August 19, 2026
The company has entered into a non-binding LOI for a reverse merger with ABL.
“has entered into a non-binding Letter of Intent ("LOI") regarding a proposed reverse merger transaction with Advanced Biological Laboratories S.A ("ABL")”
SEC filings · December 19, 2025
COVID-19 diagnostic testing ceased in May 2025.
“ceased providing COVID-19 diagnostic testing in May 2025.”
SEC MD&A · June 30, 2026
Risks & what to watch (4)›
Key risks
- Severe cash shortage — Only $20,000 cash as of June 30, 2026, with a $55.3M working capital deficit [sec_mda · as of 2026-08-19].
- Going concern uncertainty — Financial statements prepared on a going concern basis with no assurance of sufficient funding [sec_mda · as of 2026-08-19].
- Reverse merger may fail — The ABL reverse merger is only a non-binding LOI and may not close [sec · filed 2025-12-19].
- Revenue loss from COVID testing — COVID-19 diagnostic testing ceased in May 2025, removing a key revenue source [sec_mda · as of 2026-06-30].
What to watch
- Completion or termination of the proposed reverse merger with ABL [sec · filed 2025-12-19].
- Ability to raise additional capital through equity/debt or strategic partnerships [sec_mda · as of 2026-08-19].
- Progress of the preclinical PIM kinase inhibitor (lb-1) toward clinical trials [pipeline].
- Any new business lines to replace lost COVID-19 testing revenue [sec_mda · as of 2026-08-19].
Sources: Pipeline · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run ProPhase Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ProPhase Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
32.9 months
OCF -$78K · Net income -$3M
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of Apr 30, 2026- % of float
- 0.7%
- Days to cover
- 0.1
- Shares short
- 30,023
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRPH short interestFrequently asked questions
What is the AI investment thesis for ProPhase Labs, Inc.?
ProPhase Labs, Inc. is a next-generation biotech, genomics and consumer products company focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds and diagnostics, currently pursuing a reverse merger with Advanced Biological Laboratories S.A.
What is ProPhase Labs, Inc.'s lead drug candidate?
ProPhase Labs, Inc.'s most advanced tracked candidate is be-smart (Preclinical) for Early detection of progression from Barrett's esophagus to esophageal adenocarcinoma.
Who is the CEO of ProPhase Labs, Inc.?
Mr. Ted William Karkus is the chief executive officer of ProPhase Labs, Inc. (PRPH).
Where is ProPhase Labs, Inc. headquartered?
ProPhase Labs, Inc. (PRPH) is headquartered in Uniondale, NY, United States.
What therapeutic areas does ProPhase Labs, Inc. focus on?
ProPhase Labs, Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.